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Abstract
The insulin-like and vasodilatatory polypeptide relaxin
(RLX), formerly known as a pregnancy hormone, has
gained interest as a potential humoral mediator in hu-
man heart failure. Controversy exists about the rela-
tion between plasma levels of RLX and the severity of
heart failure. The present study was designed to deter-
mine the course of RLX, atrial, and brain natriuretic
peptide (NT-proANP and NT-proBNP) during physi-
cal exercise in patients with ischemic heart disease
(IHD) and to relate hormone levels to peak cardiac
power output (CPO) as a measure of cardiopulmonary
function with prognostic relevance. 40 patients with
IHD were studied during right-heart-catheterization at
rest and during supine bicycle ergometry. RLX, NT-
proBNP, and NTproANP were determined before,
during exercise, and after recovery. NT-proANP and
NT-proBNP levels increased during maximal charge,
and recovery while RLX levels decreased. Cardiac
power output at maximal charge correlated inversely
with NTproANP and NTproBNP but positively with
RLX. Patients with high degree heart failure
(CPO<1.96 W) had higher NTproANP and NTproB-
NP and lower RLX levels than patients with low de-
gree heart failure. While confirming the role of NT-
proANP and NTproBNP as markers for the severity
of heart failure, the present data do not support the
concept that plasma levels of RLX are related to the
severity of myocardial dysfunction and that systemic
RLX acts as a compensatory vasodilatatory response
hormone in ischemic heart disease.
Key words: Heart failure, coronary artery disease, car-
diorenal integration, natriuretic peptides, hemodynam-
ics, right heart catheterization.
INTRODUCTION
The insulin-like polypeptide relaxin (RLX), formerly
known as a pregnancy hormone [1], has gained interest
as a potential humoral mediator in human heart failure
[2]. Dschietzig and coworkers [3] have shown that the
plasma levels of RLX are increased in relation to the
severity of myocardial dysfunction, that the heart is a
relevant source of RLX during cardiac failure, and that
plasma RLX concentrations are related to left ventricu-
lar filling pressures. Comparably, Fisher and coworkers
observed high RLX levels in patients with heart failure
[4]. In contrast, Kupari and coworkers [5] failed to de-
tect increased plasma RLX levels in patients with aortic
valve disease but confirmed that the heart is capable of
producing RLX during heart failure states.
Krueger et al. analyzed the effects of physical exer-
cise on plasma RLX levels in patients with heart fail-
ure in comparison with healthy controls and observed
that plasma RLX levels neither were different between
groups nor changed during physical exercise [6]. How-
ever, this study investigated a heterogeneous group of
heart failure patients including subjects with idiopathic
cardiomyopathy as well as patients with ischemic heart
disease. Additionally the study did not relate RLX lev-
els to hemodynamics and the plasma concentrations
of natriuretic peptides.
The present study was thus designed to determine
the effects of physical exercise (bicycle ergometry) on
the plasma levels of RLX and N-terminal pro A and B
type natriuretic peptides (NTproANP and NTproB-
NP, respectively) as established humoral markers for
the severity of myocardial dysfunction in a homoge-
neous group of patients with ischemic heart disease of
different severity. Additionally, the relationsship be-
tween cardiac power output at maximal charge and the
respective hormone levels were analyzed.
MATERIALS AND METHODS
The investigation conforms with the principles out-
lined in the Declaration of Helsinki. Following ap-
proval by the institutional review board and written in-
formed consent, 40 medical patients with ischemic
heart disease were studied during routine right-heart-
catheterization (RHC). None of the female patients
was at childbearing age. Demographic data are given in
Table 1. Left ventricular ejection fraction was deter-
mined echocardiographically before RHC.
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30 min resting period in the supine position a pul-
monary artery catheter (Edwards Lifescience, Irvine,
USA) was inserted via the brachial vein of the non-
dominant arm. Cardiac output was determined by bo-
lus thermodilution. The results are given as the aver-
age of three measurements. Arterial blood pressure
was determined oscillometrically, heart rate was deter-
mined by electrocardiography.
The hemodynamic variables measured were: mean
arterial pressure (MAP), cardiac output and index (CO
and CI), central venous pressure (CVP), systolic,
mean, diastolic and occlusion pulmonary artery pres-
sures (PAPS, PAPM, PAPD, PAOP), and mixed ve-
nous saturation (SvO2). Peak cardiac power output
was calculated as CO x MAP x 0.00222 during maxi-
mal charge
Pulmonary arterial blood samples for the determi-
nation of RLX, NTproANP, and NTproBNP were
drawn from the pulmonary artery. Blood was sampled
in EDTA-tubes containing 5000 U aprotinine (Trasy-
lol, Bayer, Germany) and immediately spun for 10
minutes at 3400 rpm. Supernatants were stored at
-70°C for further analysis.
After completing the baseline measurements (t1),
the patients performed an ergometric test in the
supine position. Starting with 25 watt, charge was in-
creased in 25 to 100 watt steps every sixth minute ac-
cording to the estimated capacity of the patient. Re-
peated measurements were performed during each
step test for a maximum of 3 steps (t2, t3, t4). Maxi-
mal charge varied from 25 to 200 watts depending on
the achievement of stop criteria.
Stop criteria were: achievement of submaximal
heart rate (200 bpm minus age), missing increase of
heart rate during charge, arterial blood pressure
>240/120 mmHg, PAOP >40 mmHg, PAPM >60
mmHg, SvO2 <40%, ST-lowering >0,2 mV, a de-
crease in arterial blood pressure during charge, angina
pectoris, shortness of breath, peripheral exhaustion,
and recurrent ventricular arrhythmias despite of repo-
sitioning the PA-catheter.
Ischemia during ergometric testing was defined as
angina pectoris combined with typical electrocardio-
graphic signs of myocardial ischemia and/or a sudden
increase in PAOP of more than 20 mmHg.
After a resting period of 10 minutes a blood analy-
ses was drawn for determination of recovery hormone
levels (t5).
DETERMINATION OF RELAXIN
RLX was determined by a sandwich-type enzyme im-
munoassay (EIA) as described previously [7]. Shortly,
this assay is based on two specific polyclonal antibod-
ies raised in rabbits against recombinant human gene
H2-RLX. The detection limit of this assay is 1.2
pg*ml-1. The standard range is 1.2 to 250 pg*ml-1. Re-
covery in plasma is 97 ± 4.5%. The intra-assay coeffi-
cient of variance at 15.3 pg * ml-1 was 9.6% (n = 18),
the inter-assay coefficient of variance at 15.6 pg * ml-1
was 10.2% (n = 12). The assay has a cross-reactivity of
less than 0.01% with insulin, insulin-like growth fac-
tor, LH, and FSH.
DETERMINATION OF NT PROANP
NTproANP was determined by a competitive-binding
radioimmunoassay with magnetic solid phase tech-
nique in a modification of Sundsfjord et al. [8] using
the same rabbit-anti-rat proANP polyclonal serum,
human proANP (1-30) from Peninsula Lab (Bachem
Ltd, St. Helene, UK) as the standard, and iodined
proANP 1-30 purified by HPLC for radiolabeling. In
order to achive high sensitivity and good precision,
Dynabeads M280 with sheep-anti-rabbit IgG (Dynal
Biotech,Oslo, Norway) as solid phase and second anti-
body were used. The coefficient of variance at 425,
1163, and 2490 pmol * l-1 was 7.5, 3.7, and 3.4%, re-
spectively. The detection limit was 30 pmol/l.
DETERMINATION OF NT PROBNP
NTproBNP was determined by an electrochemolumi-
nescence immunoassay (Elecsys proBNP sandwich
immunoassay; Roche Diagnostics, Basel, Switzerland)
on Elecsys 2010 [9]. The mean intraassay variance was
4.3% (range: 2.7 to 5.9% for plasma samples with a
concentration between 7.6 to 2732 pmol * l-1 with an
interassay variance of 3.2%). The lower detection limit
was 0.6 pmol * l-1.
STATISTICAL ANALYSES
Following the observation that only 23 of the patients
were capable of performing all exercise steps and that
8 patients achieved the stop criteria already during ex-
ercise step 1, peak charge levels for hemodynamic and
hormonal parameters were used for further analysis to
achieve comparability between individuals.
After the ergometric testing, patients were grouped
according to peak cardiac power output. As suggested
by Williams and coworkers [10], a cut-off value < 1.96
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Table 1. Demographics.
Age (years) 60 (38-78)
Weight (kg) 84 (63 – 115)
Height (cm) 175 (160 – 190)
Male/Female 35/5







Plasma creatinine [mmol*l-1] 65 (52 – 103)
Demographic data and plasma creatinine levels of 40 patients
undergoing ergometric exercise testing. Data are median ±
range. LVEF: left ventricular ejection fraction (echocardio-
grapy); AOD: arterial occlusive disease; AH: arterial hyper-
tension; MI: myocardial infarction; CABG: coronary artery
bypass grafting.
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degree (HDHF: n = 18) and low degree heart failure
(LDHF: n = 22).
Data are given as median ± range. With respect to
the high variability of baseline hormone levels, data
were analyzed non-parametrically. Friedman’ test fol-
lowed by Wilcoxon’s matched pairs test was used for
intra-individual comparisons. Mann-Whitney U test
was applied for analyses of differences between the
HDHF and the LDHF group. Fisher’ s exact test was
used to analyze between group differences of nominal
variables. Correlation analyses were performed by
Spearman’s rank correlation test. A p-value of less
than 0.05 indicates statistical significance; p = n.s. de-
notes no statistical significance.
RESULTS
All patients underwent successful ergometric testing.
No complications related to the right heart catheteri-
zation occurred. Five patients in the HDHF group but
none in LDHF were tested postive for myocardial is-
chemia (p = 0.013).
HEMODYNAMICS
The course of hemodynamics is given in Table 2,
showing that exercise was associated with profound
changes in cardiac index, mean arterial pressure, mixed
venous saturation and filling pressures. Peak cardiac
power output (CPO) at the individual maximal charge
was 2.7 (1.2 – 5.5) W.
Analysis of between group differences in the
HDHF and the LDHF groups revealed that the
HDHF group (peak CPO: 1.46 (1.04-1.86) W) had
higher baseline pulmonary artery pressures (data not
shown) and PAOP levels (10 (4-28) vs. 6 (4-14)
mmHg, p = 0.03), a lower baseline SvO2 (63 (58-73)
vs. 69 (63-75) %, p = 0.002), higher peak exercise
PAOP (31 (13-43) vs. 23 (7-35) mmHg, p = 0.005) but
lower MAP (111 (98-126) vs. 122 (100-142) mmHg, p
= 0.02) and CI (3.6 (2.7-4.8) vs. 6.3 (4.3-9.4), p
<0.0001) than the LDHF group.
Differences in demographics and medication in
both groups is given in Table 3, showing that patients
in the HDHF group were more frequently tested posi-
tively for ischemia during exercise and were more fre-
quently treated with digitalis.
HORMONES
The course of NTproANP, NTproBNP and RLX in
all patients is given in Figure 1, showing that both na-
triuretic peptides increased modestly during maximal
charge and recovery and that RLX levels during recov-
ery were significantly lower than baseline levels.
The course of hormones in the HDHF and the
LDHF groups is depicted in Figure 2, showing that
plasma NTproANP and NTproBNP levels were high-
er and RLX levels were lower in the HDHF in com-
parison with the LDHF group. NTproANP and NT-
proBNP in the EDHF and the LDHF increased com-
parably to the changes observed in all patients (Fig. 2)
while no significant changes in plasma RLX were ob-
served.
Individual changes in RLX levels in the HDHF and
LDHF group are given in Figure 3 a. and 3.b, showing
a high variability at baseline and heterogenous re-
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Table 2. Hemodynamics.
t1 t2 t3 t4
n 40 40 32 23
charge 25 50 100
[W] (25-25) (50-100) (75-200)
CI 2.9 3.4* 4.6* 6.3*
[l/min/m2] (1.4-4.4) (2.5-5.3) (3.1-7.2) (4.3-9.4)
MAP 92 112* 112* 121*
[mmHg] (75-126) (83-116) (95-114) (100-140)
HR 68 88* 105* 122*
[bpm] (44-95) (62-114) (70-134) (102-173)
SvO2 66 41* 36* 32*
[%] (58-75) (27-58) (21-55) (20-49)
CVP 4 16 9 9*
[mmHg] (2-12) (7-26) (8-11) (4-15)
PAPM 15 34* 36* 36*
[mmHg] (10-36) (15-65) (21-52) (22-56)
PAOP 8 20* 20* 23*
[mmHg] (4-28) (9-43) (8-35) (7-39)
The course of hemodynamics in 40 patients with ischemic heart disease undergoing ergometric bicycle testing. t1: Baseline after
30 min rest; t2 to t4: ergometric testing with increasing charges. CI: cardiac index; MAP: mean arterial blood pressure, HR: heart
rate; SvO2: mixed venous oxygen saturation; CVP: central venous pressure; PAPM: mean pulmonary artery pressure; PAOP:
pulmonary artery occlusion pressure. *: significant difference (p < 0.05) in comparison with t1 (Friedman’s test followed by
Wilcoxon’s matched pairs test).
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From baseline to recovery RLX increased in 8 and de-
creased in 10 patients in the HDHF-group and in-
creased in 14 but decreased in 8 patients in the LDHF-
group.
CORRELATION ANALYSES
Correlation analyses revealed no correlation between
RLX baseline plasma levels and corresponding hemo-
dynamic indices and the EF. Inverse correlations be-
tween RLX levels and NTproANP (Spearman’s rho
(r/R) = -0.33, p = 0.047) and NTproBNP (r/R =
-0.41, p = 0.013) were observed. The correlation be-
tween RLX baseline levels and peak CPO was r/R =
0.48 (p = 0.0056).
In contrast, NTproANP and NTproBNP baseline
levels were strongly to moderately associated with he-
modynamic parameters at rest (NTproANP vs: EF:
r/R = -0.36 (p = 0.02); PAPS: r/R=0.72 (p <0.0001);
PAPD: r/R = 0.67 (p <0.0001); PAPM: r/R = 0.66 (p
<0.0001); PAOP: r/R = 0.71 (p <0.0001); SvO2: r/R
= -0.47 (p = 0.0045); NTproBNP vs: EF: r/R = -0.52
(p = 0.008); PAPS: r/R = 0.53 (p = 0.0016); PAPD:
r/R = 0.48 (p = 0.004); PAPM: r/R = 0.48 (p =
0.0038); PAOP: r/R = 0.51 (p = 0.0021); SvO2: r/R =
-0.38 (p = 0.02)). The correlation between NT-
proANP and NTproBNP baseline levels and peak
CPO was r/R = -0.55 (p = 0.0045) and r/R = -0.66 (p
<0.0001), respectively.
Only minor correlations were observed between he-
modynamics changes from baseline to maximal charge
and changes in RLX and NTproANP (delta MAP vs.
delta RLX: r/R = 0.35 (p = 0.046); delta NTproANP
vs. delta PAOP: r/R = 0.39 (p = 0.0025); delta
NTproANP vs. delta SVI: r/R = -0.35 (p = 0.044);
delta NTproANP vs. delta proBNP: r/R = 0.39 (p =
0.027)).
DISCUSSION
Recently, Dschietzig el al. suggested that the polypep-
tide RLX is “an important player in heart failure“ [3].
This assumption was based on the observation that
the heart is a RLX net producer in heart failure states
and that the plasma levels of RLX in a study in pa-
tients presenting with acute cardiac decompensation
were closely related to left ventricular filling pressures
and the clinical severity of myocardial dysfunction.
Additionally this group showed that RLX is a func-
tional antagonist of the vasoconstrictory effects of
endothelin-1; suggesting that the increase of RLX in
heart failure may be a compensatory response [2].
However, data from other groups on the role of RLX
in heart failure are controversial. Fisher and coworkers
reported that increased plasma RLX levels in heart
failure patients have no prognostic relevance and
failed to detect a meaningful correlation between this
hormone an NTproBNP as an accepted humoral
marker of myocardial dysfunction [4]. Comparably,
Kupari and coworkers did not detect any correlation
between plasma RLX levels and “any measure of car-
diac structure or function“ in a group of patients with
isolated aortic valve disease [5], and Krüger et al. [6]
did not observe any difference in RLX levels at base-
line as well as at peak exercise in compensated heart
failure patients compared to a healthy control group.
Thus obviousy the RLX impact in the setting of hu-
man heart failure has not been satisfactorily solved.
Right heart catherization with ergometric testing is
an established method for the quantification of car-
diac dysfunction under different loading conditions.
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Table 3. Demographic data and medication in the LDHF and HDHF groups.
LDHF (n = 22) HDHF (n = 18) sign.
Age (years) 59 (38-64) 60 (39-78) n.s.
Weight (kg) 86 (70 – 115) 82 (63-91) n.s.
Height (cm) 180 (160 – 190) 172 (160 -185) n.s.
Male/Female 21/1 14/4 n.s.
LVEF [%] 60 (20 – 65) 45 (30 – 60) n.s.
Previous MI [yes/no] 18/4 10/8 n.s.
Previous CABG [yes/no] 10/22 9/18 n.s
Previous PCI [yes/no] 11/22 10/18 n.s.
Pos. ischemia testing [yes/no] 0/22 5/13 p = 0.013
Duration of IHD [months] 1 (1-50) 2 (1 – 120) n.s.
Betablocker [yes/no] 22/0 18/0 n.s.
ACE-inhibitor/ARB [yes/no] 17/5 17/1 n.s.
Diuretics [yes/no] 5/17 9/9 (p = 0.08)
Aldosterone-Blocker [yes/no] 0/22 1/17 n.s.
Digitalis [yes/no] 2/20 7/11 p = 0.025
Demographic data and medication of patients with ischemic heart disease (IHD) grouped according to the results of ergometric
exercise testing in a high degree heart failure (HDHF) and a low degree heart failure group (LDHF). Data are median ± range.
LVEF: left ventricular ejection fraction (echocardiograpy); MI: myocardial infarction; CABG: coronary artery bypass grafting;
PCI: percutaneus coronary intervention; positive ischemia testing: please see text for details; ARB: angiotensin receptor blocker.
p < 0.05: significant between group difference (continuous data: Mann-Whitney U, nominal data: Fisher’s exact test).
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diac index and filling pressures) that may be used for
quantification of cardiac function, peak cardiac power
output – the product of cardiac output and mean arte-
rial blood pressure – is a measure of myocardial dys-
function of prognostic relevance [10] which integrates
cardiac output and ventricular afterload [11].
The results of our study question the role of plas-
matic RLX as a compensatory humoral mediator in
human heart failure: We neither did observe any direct
correlation between plasma RLX and hemodynamic
function at rest nor a positive correlation with NT-
proANP or NTproBNP baseline levels. In contrast,
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Fig. 1. The course of the plasma levels of the N-terminal
prohormones of the A- and B-type natriuretic peptides (NT-
proANP, NTproBNP) and relaxin (RLX) in patients with is-
chemic heart disease undergoing physical exercise testing.
Baseline: after 30 min supine rest; max. charge: during peak
exercise; recovery: 10 min after peak exercise. Data are given
as box blots . P-values denote a significant difference versus
baseline (Friedman’s test followed by Wilcoxon’s matched
pairs test).
Fig. 2. The course of the plasma levels of the N-terminal
prohormones of the A- and B-type natriuretic peptides (NT-
proANP, NTproBNP) and relaxin (RLX) in patients with is-
chemic heart disease undergoing ergometric exercise testing
grouped according to peak cardiac power output (CPO) less
or greater than 1.96 W. Baseline: after 30 min supine rest;
max. charge: during peak exercise; recovery: 10 min after
peak exercise. High degree heart failure (open box plots: peak
CPO <1.96 W; n = 18); low degree heart failure (grey box
plots: CPO >1.96 W; n = 22). P-values denote significant dif-
ferences between groups (Mann-Whitney - U test). Fried-
man’s test followed by Wilcoxon’s matched pairs test re-
vealed significant within group changes in NTproANP and
NTproBNP levels and no significant changes in plasma RLX.
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ic peptides at baseline and a positive correlation be-
tween RLX and peak CPO were detected. Additional-
ly, RLX levels tended to decrease during exercise and
decreased during recovery during exercise (in the
whole group), showed a highly variable and inhomoge-
neous response pattern in the HDHF and the LDHF
group, and were lower in patients with more severe
myocardial dysfunction. It is of note that we have re-
cently shown that plasma RLX levels in healthy volun-
teers were higher than those reported by Dschietzig
and coworkers for patients with severe myocardial fail-
ure [7].
It remains to be determined how the discrepancies
between the above mentioned studies can be ex-
plained; even taking into account that Dschietzigs pa-
tients were in acute heart failure while the patients in
the other studies were performed in stable patients
with either chronic heart failure [4, 5, 6] or as in the
present study in patients with ischemic heart disease
and varying degree of myocardial dysfunction. Inter-
estingly, patients in the HDHF group were more fre-
quently tested positive for ischemia during exercise.
The neurohumoral response in these patients may thus
– at least in part - be more intensively influenced by
myocardial ischemia than by myocardial failure. How-
ever, plasma levels of RLX were not significantly dif-
ferent between patients with or without ischemia dur-
ing the study period (data not shown). Comparably,
patients in the HDHF were more frequently treated
with digitalis and as a trend (p = 0.08) more frequently
with diuretics. Since no data are available on the ef-
fects of acute myocardial ischemia, digitalis, and di-
uretics on plasma levels of RLX any attempt to ex-
plain the findings of the present study on the basis of
these differences remains speculative.
It is of note that the immunoassay kit in all studies
mentioned so far was purchased from the same manu-
facturer. In contrast to Dschietzig and coworkers (per-
sonal communication), we added aprotinine during
blood sampling to prevent protein degradation. This,
however, may explain absolut differences in RLX lev-
els between both studies but does not help to explain
the lack of relative differences, i.e the fact that patients
with more severe myocardial dysfunction had lower
RLX levels. Consequently, variations in laboratory
technology are not helpful in explaining the contradic-
tory results between Dschietzigs [3] and our findings.
It is of note that the analyses in the present study were
performed in the reference laboratory of the manufac-
turer (Immundiagnostik AG), rendering possible er-
rors in the analytical technique rather unlikely.
With respect to the pleiotropic effects of RLX, sev-
eral alternative explanations for these discordant re-
sults may be conceivable. For example, plasma RLX
levels have been shown to be related to insulin sensi-
tivity and serum fibrinogen levels in female patients
with type 2 diabetes mellitus [12, 13], suggesting, that
this „“insulin-like“ hormone is indeed related to
changes in metabolism.
Additionally, a lack of systemic changes in RLX lev-
els does not exclude effects of this hormone on the
organ or cellular levels. This may be derived from the
observation that acute volume loading in healthy vol-
unteers leads to a significant increase in urinary excre-
tion of RLX despite unchanged plasma RLX levels [7].
Variable results have been reported on the role of
RLX as a paracrine humoral mediator in the cardiovas-
cular system. In a very recent publication, Dschietzig
an coworkers have shown upregulation of RLX
mRNA-transcription and RLX protein content in the
left atria and ventricles of spontaneous hypertensive
rats in comparison with nonhypertensive Wistar Kyoto
rats and a close inverse correlation between left atrial
and ventricular relative myocardial mass and the RLX
protein content [14], suggesting that this peptide may
exert antihypertrophic effects in this model of in-
creased vascular resistance. It is not known, if RLX
may have comparable effects in humans.
In contrast to RLX, NTproANP and NTproBNP
were highly accurate in differentiating between pa-
tients with less and more severe myocardial dysfunc-
tion, either in the resting state as well as during exer-
cise. This supports the well established role of these
hormones for the detection of myocardial failure [9].
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Fig. 3. The individual changes in plasma relaxin (RLX) levels
in patients with ischemic heart disease undergoing ergometric
exercise testing grouped according to peak cardiac power out-
put (CPO) less or greater than 1.96 W. Baseline: after 30 min
supine rest; max. charge: during peak exercise; recovery: 10
min after peak exercise. a. high degree heart failure (peak
CPO <1.96 W; n = 18); b. low degree heart failure (CPO
>1.96 W; n = 22). Friedman’s test followed by Wilcoxon’s
matched pairs test revealed no significant within group
changes. Please note the different scales on the y-axes.
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Few data is available about the course of NTproB-
NP during physical exercise and no data exists about
NTproANP. Scharhag et al. observed that NTproBNP
increased after a walking test in patients with IHD and
that patients with more severe myocardial dysfunction
showed a more pronounced increase of this hormone
30 min after exercise. In contrast to our data, no cor-
relation between NTproBNP baseline levels and peak
cardiac power output was observed. [15]. The changes
in NTproANP levels were less pronounced as it has
been shown for the active compound ANP [16]. This
may be explained by the different plasma half-lifes and
the higher plasma levels of the N-terminal prohor-
mones in comparison with the active hormones.
In summary, the data presented in this study clearly
shows that patients with ischemic heart disease and
myocardial dysfunction - diagnosed by invasive hemo-
dynamic parameters – present with lower levels of
plasma relaxin than patients with preserved myocardial
function and that plasma RLX levels are inversely re-
lated to the severity of heart disease in these patients.
Therefore, in our opinion, the significance of RLX as
an important compensatory hormone in IHD patients
has not been clearly answered so far.
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